| Title |
RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis
|
|---|---|
| Published in |
OncoTargets and therapy, January 2017
|
| DOI | 10.2147/ott.s124417 |
| Pubmed ID | |
| Authors |
Feiyan Shou, Feng Xu, Gang Li, Zhenhua Zhao, Ying Mao, Fangfang Yang, Hongming Wang, Hangyuan Guo |
| Abstract |
Previous studies have reported that Ras-associated domain family 1A (RASSF1A), the most commonly silenced tumor suppressor via promoter methylation, played vital roles in the development of carcinogenesis. The purpose of this meta-analysis was to determine whether RASSF1A promoter methylation increased the risk of thyroid cancer. PubMed, Embase, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure databases were searched to obtain eligible studies. The pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of the associations, using Stata 12.0 software. The methodological quality of included studies was evaluated using Newcastle-Ottawa scale table. Egger's test and Begg's test were applied to detect publication biases. TSA 0.9 software was used to calculate the required information size and whether the result was conclusive. A total of 10 articles with 12 studies that included 422 thyroid cancer patients, identifying the association of RASSF1A promoter methylation with thyroid cancer risk, were collected in this meta-analysis. Overall, RASSF1A promoter methylation significantly increased the risk of thyroid cancer (total, OR=8.27, CI=4.38-15.62, P<0.05; Caucasian, OR=9.25, CI=3.97-21.56, P<0.05; Asian, OR=7.01, CI=2.68-18.38, P<0.05). In the subgroup analysis based on sample type, a significant association between thyroid cancer group and control group was found (normal tissue, OR=9.55, CI=4.21-21.67, P<0.05; adjacent tissue, OR=6.80, CI=2.49-18.56, P<0.05). The frequency of RASSF1A promoter methylation in follicular thyroid carcinoma was higher than in control group (OR=11.88, CI=5.80-24.32, P<0.05). In addition, the results indicated that the RASSF1A promoter methylation was correlated with papillary thyroid carcinoma in Caucasians and Asians (total, OR=8.07, CI=3.54-18.41, P<0.05; Caucasian, OR=11.35, CI=2.39-53.98, P<0.05; Asian, OR=6.67, CI=2.53-17.64, P<0.05). On the basis of the trial sequential analysis, the significant association of RASSF1A promoter methylation with thyroid cancer risk was found, and there was no need to perform further studies. This meta-analysis confirms that RASSF1A promoter methylation is a risk factor for thyroid tumor. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| China | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 18 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 17% |
| Researcher | 3 | 17% |
| Student > Bachelor | 2 | 11% |
| Student > Ph. D. Student | 2 | 11% |
| Professor | 1 | 6% |
| Other | 2 | 11% |
| Unknown | 5 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 33% |
| Biochemistry, Genetics and Molecular Biology | 4 | 22% |
| Neuroscience | 1 | 6% |
| Agricultural and Biological Sciences | 1 | 6% |
| Unknown | 6 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2017.
All research outputs
#16,721,717
of 25,374,647 outputs
Outputs from OncoTargets and therapy
#982
of 3,016 outputs
Outputs of similar age
#255,077
of 421,655 outputs
Outputs of similar age from OncoTargets and therapy
#35
of 64 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 421,655 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.